Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

Gilead Science’s Kite Pharma is separating from its cell therapy joint venture with Fosun Pharma in China, handing Fosun the ...

Northmor will host Danville in what has become one of the most competitive games on the KMAC schedule. The Blue Devils own a ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

20 January 2022 Gilead Sciences has sued an array of pharmaceutical suppliers and distributors accusing them of forming a ...

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Climate change and conflict risk overshadowing efforts to improve people's health, when in reality the issues overlap, Peter ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Raymond James has recently raised Gilead Sciences, Inc. (GILD) stock to Outperform rating, as announced on July 8, 2024, according to Finviz. Earlier, on May 1, 2024, Maxim Group had reiterated the ...